|Videos|April 21, 2023
HER2-Amplified Colorectal Cancer: Clinical Trial Data
A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
Dr Spira on the Data Supporting the Phase 3 Development of Iza-Bren in EGFR-Mutant NSCLC
5